Abstract
Abstract Inflammatory Breast Cancer (IBC) is a unique and aggressive disease, constituting 2 - 4% of breast cancer diagnoses yet responsible for up to 10% of breast cancer related deaths. IBC remains a clinical diagnosis, without highly specific molecular markers, and the genomic drivers of the disease are incompletely characterized. The overrepresentation of human epidermal growth factor 2 amplification and triple-negative disease within IBC have confounded comparisons between IBC and non-IBC. Nonetheless, some consistent genomic observations have emerged that may begin to explain the characteristic behavior of IBC, supported by both comparative clinical studies and preclinical models. This session will review mutational analysis, gene expression profiling, and epigenetic findings that highlight similarities as well as subtle differences between IBC and non-IBC. Citation Format: F. Howard. Is inflammatory breast cancer a genomically different type of breast cancer? [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr ED11-01.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
